These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15060715)

  • 1. [The dosage of botulinum toxin type B in adductor type spasmodic dysphonia].
    Schönweiler R; Zwirner P
    HNO; 2005 Feb; 53(2):166-73. PubMed ID: 15060715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study.
    Upile T; Elmiyeh B; Jerjes W; Prasad V; Kafas P; Abiola J; Youl B; Epstein R; Hopper C; Sudhoff H; Rubin J
    Head Face Med; 2009 Oct; 5():20. PubMed ID: 19852852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
    Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
    J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
    Blitzer A; Brin MF; Stewart CF
    Laryngoscope; 1998 Oct; 108(10):1435-41. PubMed ID: 9778279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of spasmodic dysphonia with botulinum toxin].
    Klap P; Marion MH; Perrin A; Fresnel-Elbaz E
    Ann Otolaryngol Chir Cervicofac; 1991; 108(8):477-82; discussion 482-3. PubMed ID: 1789624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results.
    Adams SG; Hunt EJ; Charles DA; Lang AE
    J Otolaryngol; 1993 Jun; 22(3):171-5. PubMed ID: 8371328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin type B for treatment of spasmodic dysphonia: a case report.
    Sataloff RT; Heman-Ackah YD; Simpson LL; Park JB; Zwislewski A; Sokolow C; Mandel S
    J Voice; 2002 Sep; 16(3):422-4. PubMed ID: 12395995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia.
    Blitzer A
    Otolaryngol Head Neck Surg; 2005 Dec; 133(6):836-8. PubMed ID: 16360499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of botulinum toxin type A injections on aerodynamic measures of spasmodic dysphonia.
    Adams SG; Durkin LC; Irish JC; Wong DL; Hunt EJ
    Laryngoscope; 1996 Mar; 106(3 Pt 1):296-300. PubMed ID: 8614192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia.
    Casserly P; Timon C
    J Laryngol Otol; 2008 Jan; 122(1):52-6. PubMed ID: 17470307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [First use of botulinum toxin type B in ENT patients with secondary therapy failure of botulinum toxin type A].
    Guntinas-Lichius O
    HNO; 2004 Jan; 52(1):53-6. PubMed ID: 14740116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
    Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
    J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia.
    Adams SG; Hunt EJ; Irish JC; Charles DA; Lang AE; Durkin LC; Wong DL
    J Otolaryngol; 1995 Dec; 24(6):345-51. PubMed ID: 8699600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin treatment for spasmodic dysphonia.
    Kobayashi T; Niimi S; Kumada M; Kosaki H; Hirose H
    Acta Otolaryngol Suppl; 1993; 504():155-7. PubMed ID: 8470525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia.
    Adler CH; Bansberg SF; Krein-Jones K; Hentz JG
    Mov Disord; 2004 Sep; 19(9):1075-9. PubMed ID: 15372600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
    Troung DD; Rontal M; Rolnick M; Aronson AE; Mistura K
    Laryngoscope; 1991 Jun; 101(6 Pt 1):630-4. PubMed ID: 2041443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
    Sulica L; Blitzer A; Brin MF; Stewart CF
    Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin injection for treatment of spasmodic dysphonia: experience at Srinagarind Hospital.
    Srirompotong S; Saeseow P; Taweesaengsuksakul R; Kharmwan S; Srirompotong S
    J Med Assoc Thai; 2006 Dec; 89(12):2077-80. PubMed ID: 17214059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternating unilateral botulinum toxin type A (BOTOX) injections for spasmodic dysphonia.
    Koriwchak MJ; Netterville JL; Snowden T; Courey M; Ossoff RH
    Laryngoscope; 1996 Dec; 106(12 Pt 1):1476-81. PubMed ID: 8948606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.